Sign in to confirm you’re not a bot
This helps protect our community. Learn more

Genprex wins FDA Fast Track designation for REQORSA with Keytruda for treating NSCLC

Proactive Investors
62.6K subscribers
1.3K views 3 years ago
Genprex Inc CEO Rodney Varner tells Proactive the FDA has granted Fast Track designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)’s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda. The Austin, Texas-based clinical-stage gene therapy company said that in the first quarter of 2022, it plans to initiate its Acclaim-2 clinical trial, which is an open-label, multicenter Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda, for this patient population. ...more
...more
Genprex wins FDA Fast Track designation for REQORSA with Keytruda for treating NSCLC
N/ALikes
1,377Views
2022Jan 3
Genprex Inc CEO Rodney Varner tells Proactive the FDA has granted Fast Track designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)’s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda. The Austin, Texas-based clinical-stage gene therapy company said that in the first quarter of 2022, it plans to initiate its Acclaim-2 clinical trial, which is an open-label, multicenter Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda, for this patient population.

Proactive Investors

62.6K subscribers